SE7500130L - - Google Patents
Info
- Publication number
- SE7500130L SE7500130L SE7500130A SE7500130A SE7500130L SE 7500130 L SE7500130 L SE 7500130L SE 7500130 A SE7500130 A SE 7500130A SE 7500130 A SE7500130 A SE 7500130A SE 7500130 L SE7500130 L SE 7500130L
- Authority
- SE
- Sweden
- Prior art keywords
- influenza
- components
- virus
- type
- cationic detergent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
1498261 Influenza vaccines SANDOZ Ltd 13 Jan 1975 [14 Jan 1974] 1290/75 Heading A5B The haemagglutinin and neuramuridase components are isolated from influenza virus by treating the virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the resulting solubilised such components from residual sub-viral particles. The virus concentrate may have a pH of from 6.5 to 8.5 and may inactivated with formaldehyde prior to the addition of the cationic detergent. After addition of the cationic detergent, the resulting mixture is preferably allowed to stand for 30 minutes to 16 hours at 4‹C to 37‹C. Influenza vaccines comprise a mixture of the haemagglutinin and neuramuridase components of an influenza virus, in the substantial absence of other components of the influenza viral particle in association with -an inertliquid diluent such as physiological saline optionally phosphate buffered. The vaccine may additionally comprise a preserving or inactivating agent such as formaldehyde and/or an immunological adjuvant such as aluminium hydroxide or aluminium phosphate. The influenza virus may be an influenza Type A, A 1 , A 2 or B virus, strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (Mutagrip), or B/Mass/67.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH44774A CH589453A5 (en) | 1974-01-14 | 1974-01-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
SE7500130L true SE7500130L (en) | 1975-07-15 |
SE427238B SE427238B (en) | 1983-03-21 |
Family
ID=4187233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE7500130A SE427238B (en) | 1974-01-14 | 1975-01-07 | SET TO INSULATE INFLUENCEVIRUS SUBSTANCES |
Country Status (27)
Country | Link |
---|---|
JP (2) | JPS58407B2 (en) |
AT (1) | AT345449B (en) |
AU (1) | AU500250B2 (en) |
BE (1) | BE824372A (en) |
CA (1) | CA1049406A (en) |
CH (1) | CH589453A5 (en) |
CS (1) | CS191254B2 (en) |
DD (1) | DD116239A5 (en) |
DE (1) | DE2500785B2 (en) |
DK (1) | DK140003B (en) |
ES (1) | ES433759A1 (en) |
FI (1) | FI54053C (en) |
FR (1) | FR2257305B1 (en) |
GB (1) | GB1498261A (en) |
HK (1) | HK56380A (en) |
HU (1) | HU173920B (en) |
IE (1) | IE40794B1 (en) |
IL (1) | IL46426A (en) |
MY (1) | MY8100204A (en) |
NL (1) | NL166622C (en) |
NO (1) | NO143128C (en) |
PH (1) | PH14458A (en) |
PL (1) | PL93689B1 (en) |
SE (1) | SE427238B (en) |
SU (1) | SU616997A3 (en) |
YU (1) | YU41289B (en) |
ZA (1) | ZA75259B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2829089A1 (en) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | SUBUNIT VACCINE |
JPH0688911B2 (en) * | 1985-06-06 | 1994-11-09 | 国立予防衛生研究所長 | Influenza vaccine and method for producing the same |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
EP0919243A1 (en) | 1997-11-25 | 1999-06-02 | Duphar International Research B.V | Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant |
DE19938767C2 (en) * | 1999-08-16 | 2002-10-24 | Tad Pharma Gmbh | subunit vaccines |
NZ567817A (en) * | 2005-11-01 | 2012-01-12 | Novartis Vaccines & Diagnostic | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
AU2008293513B2 (en) * | 2007-08-28 | 2013-11-21 | Nanotherapeutics, Inc. | Method for producing viral vaccines |
EP3068791B1 (en) | 2013-11-15 | 2020-07-29 | Novartis AG | Removal of residual cell culture impurities |
-
1974
- 1974-01-14 CH CH44774A patent/CH589453A5/xx not_active IP Right Cessation
-
1975
- 1975-01-06 DK DK1475AA patent/DK140003B/en not_active IP Right Cessation
- 1975-01-06 FI FI750014A patent/FI54053C/en not_active IP Right Cessation
- 1975-01-06 NO NO750031A patent/NO143128C/en unknown
- 1975-01-07 SE SE7500130A patent/SE427238B/en not_active IP Right Cessation
- 1975-01-10 NL NL7500301.A patent/NL166622C/en not_active IP Right Cessation
- 1975-01-10 DE DE2500785A patent/DE2500785B2/en active Granted
- 1975-01-13 DD DD183614A patent/DD116239A5/xx unknown
- 1975-01-13 GB GB1290/75A patent/GB1498261A/en not_active Expired
- 1975-01-13 HU HU75SA2736A patent/HU173920B/en not_active IP Right Cessation
- 1975-01-13 ES ES433759A patent/ES433759A1/en not_active Expired
- 1975-01-13 IE IE59/75A patent/IE40794B1/en unknown
- 1975-01-13 IL IL46426A patent/IL46426A/en unknown
- 1975-01-13 CA CA217,790A patent/CA1049406A/en not_active Expired
- 1975-01-13 PL PL1975177303A patent/PL93689B1/pl unknown
- 1975-01-13 AT AT21475A patent/AT345449B/en not_active IP Right Cessation
- 1975-01-13 PH PH16702A patent/PH14458A/en unknown
- 1975-01-13 YU YU58/75A patent/YU41289B/en unknown
- 1975-01-14 CS CS75255A patent/CS191254B2/en unknown
- 1975-01-14 SU SU752101722A patent/SU616997A3/en active
- 1975-01-14 AU AU77305/75A patent/AU500250B2/en not_active Expired
- 1975-01-14 FR FR7501007A patent/FR2257305B1/fr not_active Expired
- 1975-01-14 BE BE152368A patent/BE824372A/en not_active IP Right Cessation
- 1975-01-14 ZA ZA00750259A patent/ZA75259B/en unknown
- 1975-01-14 JP JP50006975A patent/JPS58407B2/en not_active Expired
-
1980
- 1980-10-09 HK HK563/80A patent/HK56380A/en unknown
-
1981
- 1981-01-29 JP JP56012831A patent/JPS6035326B2/en not_active Expired
- 1981-12-30 MY MY204/81A patent/MY8100204A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2684792A (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
SE7500130L (en) | ||
KR850001700A (en) | Method for preparing Herpes Simplex Virus Subuait Vaccine | |
US3674864A (en) | Process for stabilizing preparations of interfering viruses | |
Kurrle et al. | Influenza virus‐specific T cell‐mediated cytotoxicity: integration of the virus antigen into the target cell membrane is essential for target cell formation | |
GB1183506A (en) | New vaccines for combating influenza and the preparation thereof | |
Bang | Filamentous forms of Newcastle virus | |
Russell et al. | Cell cooperation in antibody responses to influenza virus. I. Priming of helper T cells by internal components of the virion | |
ES8104405A1 (en) | Influenza virus vaccines, process for preparing them and process for propagating influenza viruses. | |
ES8203225A1 (en) | Process for isolating viral glycoproteic antigens, and its use in the preparation of vaccines. | |
GB1292803A (en) | Improvements relating to the production of antigens | |
ES432385A1 (en) | Influenza vaccines | |
Wilcox et al. | Soluble Antigens of Vaccinia-infected Mammalian Cells II. Time Course of Synthesis of Soluble Antigens and Virus Structural Proteins | |
GB2001326A (en) | Glycoproteins from paramyxovirus and vaccines therefrom | |
IE40180L (en) | Influenza virus vaccines. | |
Russell et al. | Mumps Viral Cytolysin: I. Action on Human Epithelial Cells in Tissue Culture | |
GB1256457A (en) | Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation | |
AU5573196A (en) | A pluripotent vaccine against enveloped viruses | |
Manischewitz et al. | The effect of mycoplasmas on replication and plaquing ability of Herpes simplex virus | |
GB660109A (en) | Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine | |
US3132073A (en) | Measles vaccine | |
GB1016586A (en) | Vaccine for immunization of dogs against distemper and hepatitis contagiosa canis | |
Greer et al. | Electron microscope study of the interaction of vaccinia virus with macrophages from immunized and nonimmunized rabbits | |
GB1434181A (en) | Vaccine for the prevention and treatment of vascular conditions | |
ES350690A1 (en) | Concentration and purification of influenza viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NUG | Patent has lapsed |
Ref document number: 7500130-5 Effective date: 19940810 Format of ref document f/p: F |